While the European Congress places precision medicine at the center of oncology, only 48.8% of Spanish centers have fully implemented the tests from the common catalog
Access to molecular tests, genetic tests, and next-generation sequencing (NGS) in cancer continues to be marked in Spain by differences between regions and hospital centers, despite the fact that these tools already occupy a central place in European oncology. This was noted by Fundación Alivia in its report on its participation in ESMO 2026, the congress of the European Society for Medical Oncology, in light of recent analyses on the implementation of molecular diagnosis in Spain.
During the congress, Agata Polińska, a board member of Fundación Alivia, co-chaired the session on access, equity, and reducing inequalities of the European patient defense program (Patient Advocacy Track). In this context, Polińska presented the talk "Voces de los pacientes sobre las desigualdades de acceso: la experiencia polaca y española". For the entity, bringing this analysis to Europe reflects a top-priority problem that continues to be in force in Spain: innovation in molecular diagnosis and personalized medicine is advancing, but not always reaching all patients on equal terms.
According to recent analyses by the Sociedad Española de Oncología Médica (SEOM), the implementation of molecular diagnosis in Spain remains unequal. The first SEOM Observatory of Precision Medicine points out that only 48.8% of centers have fully implemented the tests from the common catalog and that, in hospitals with 200 to 500 beds, that percentage drops to 25.8%. In practice, this means that access to these tests continues in many cases to depend on the region, the size of the hospital, and its care pathways.
At a time when tools such as NGS make it possible to identify tumor alterations with greater precision and to guide treatment decisions more effectively, Fundación Alivia warns that this inequality has consequences for patients. When a molecular test is not requested on time, is not available, or is not part of the usual care pathway, key decisions about treatment can also be delayed or options that do exist for therapy may no longer be possible.
"Innovation only serves if it reaches the patient. Today we know that molecular tests can make a difference in diagnosis and in treatment, but this advance cannot depend on where a person lives or on the hospital where they are treated", says Xavier Pla, head of Programs at Fundación Alivia.
Fundación Alivia emphasizes that Spain has taken important steps to integrate these capabilities into the healthcare system, but considers that the challenge now is to ensure that its implementation is real and homogeneous for all patients.
About Fundación Alivia
Fundación Alivia has helped cancer patients in Spain since 2021. Among its main projects are OncoIndex, a portal that shows access to cancer treatments based on current medical knowledge; Oncomapa, a directory of doctors and clinics; and the OncoLibrería, with informational resources for patients.